Amantadine

Generic Name: Amantadine

Brand Names: Gocovri, Osmolex

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₇N

CAS Number: 768-94-5

Unique Ingredient Identifier: BF4C9Z1J53

Background: An antiviral that is used in the prophylactic or symptomatic treatment of influenza A. It is also used as an antiparkinsonian agent, to treat extrapyramidal reactions, and for postherpetic neuralgia. The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.

Indication: For the chemoprophylaxis, prophylaxis, and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Also for the treatment of parkinsonism and drug-induced extrapyramidal reactions.

Associated Conditions: Dyskinesia, Extrapyramidal disorder caused by neuroleptic drugs without Tardive dyskinesia, Influenza A Virus Infection, Parkinson's Disease (PD), Parkinson's Disease With Wearing-off Motor Fluctuations, Parkinsonism

Clinical Trials

Amantadine and L-DOPA-induced Dyskinesia in Early Parkinson's Disease

Phase 2

Completed

Conditions: Parkinson Disease

Interventions: Drug: Amantadine
Drug: placebo

First Posted Date: 2012-02-24

Last Posted Date: 2021-02-05

Lead Sponsor: University Hospital, Toulouse

Target Recruit Count: 210

Registration Number: NCT01538329

Locations: 🇫🇷
CHU de Strasbourg, Strasbourg, France
🇫🇷
CH Jean Rougier, Cahors, France
🇫🇷
CHU Dupuytren, Limoges, France

and more 15 locations

Urinary Excretion of Acetylamantadine by Normal Healthy Volunteers

Not Applicable

Completed

Conditions: Healthy Metabolism

Interventions: Drug: Amantadine

First Posted Date: 2011-11-08

Last Posted Date: 2013-07-29

Lead Sponsor: University of Manitoba

Target Recruit Count: 20

Registration Number: NCT01467258

Locations: 🇨🇦
St. Boniface General Hospital, Winnipeg, Manitoba, Canada

Dextromethorphan, Amantadine and Glucose Homeostasis in Diabetes Subjects

Phase 2

Completed

Conditions: Type 2 Diabetes Mellitus

First Posted Date: 2011-09-28

Last Posted Date: 2012-07-12

Lead Sponsor: Profil Institut für Stoffwechselforschung GmbH

Target Recruit Count: 20

Registration Number: NCT01441986

Locations: 🇩🇪
Profil Institute for Metabolic Research, Neuss, NRW, Germany

Effect of Intravenous Amantadine on Gait Freezing in Parkinson's Disease

Phase 4

Completed

Conditions: Parkinson's Disease

Interventions: Drug: amantadine sulfate
Drug: 0.9% sodium chloride

First Posted Date: 2011-03-14

Last Posted Date: 2012-08-09

Lead Sponsor: Jee-Young Lee

Target Recruit Count: 46

Registration Number: NCT01313845

Locations: 🇰🇷
Hanyang University Medical Center, Seoul, Korea, Republic of
🇰🇷
Seoul National University Bundang Hospital, Seongnam, Korea, Republic of
🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

and more 1 locations

Pilot Study of Maintenance Therapy With Intravenous AMANTADINE

Not Applicable

Conditions: Parkinson Disease

Interventions: Drug: Amantadine

First Posted Date: 2010-08-27

Last Posted Date: 2010-10-13

Lead Sponsor: Rabin Medical Center

Target Recruit Count: 20

Registration Number: NCT01190553

Amantadine Versus Ritalin in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD)

Phase 2

Conditions: Attention Deficit Hyperactivity Disorder

Interventions: Drug: Amantadine
Drug: ritalin

First Posted Date: 2010-04-06

Last Posted Date: 2010-11-18

Lead Sponsor: Tehran University of Medical Sciences

Target Recruit Count: 40

Registration Number: NCT01099059

Locations: 🇮🇷
Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of

Validation of Dyskinesia Rating Scales

Phase 4

Completed

Conditions: Parkinson's Disease

Interventions: Drug: Placebo
Drug: Amantadine

First Posted Date: 2010-02-19

Last Posted Date: 2022-12-29

Lead Sponsor: Rush University Medical Center

Target Recruit Count: 68

Registration Number: NCT01071395

Locations: 🇺🇸
Oregon Health & Science University (OHSU), Portland, Oregon, United States
🇺🇸
Duke University, Durham, North Carolina, United States
🇺🇸
University of Alabama-Birmingham (UAB), Birmingham, Alabama, United States

and more 5 locations

Amantadine as Adjunctive Therapy to Antipsychotics in Schizophrenia

Phase 3

Conditions: Schizophrenia

Interventions: Drug: Placebo
Drug: Amantadine

First Posted Date: 2009-10-21

Last Posted Date: 2011-02-16

Lead Sponsor: Hospital de Clinicas de Porto Alegre

Target Recruit Count: 40

Registration Number: NCT00999505

Locations: 🇧🇷
Hospital de Clinicas de Porto Alegre, Porto Alegre, RS, Brazil

Study of Amantadine for Risperidone Consta or Paliperidone Treated Patients to Decrease Prolactin Elevation

Phase 4

Terminated

Conditions: Schizophrenia
Schizoaffective Disorder

Interventions: Drug: Amantadine Hydrochloride, USP
Drug: Placebo

First Posted Date: 2009-09-11

Last Posted Date: 2013-06-10

Lead Sponsor: David C. Henderson, MD

Target Recruit Count: 6

Registration Number: NCT00975611

Locations: 🇺🇸
Freedom Trail Clinic, Boston, Massachusetts, United States

Effectiveness of Amantadine Hydrochloride for Treatment of Severe Traumatic Brain Injury (TBI)

Phase 2

Completed

Conditions: Traumatic Brain Injury

Interventions: Drug: Amantadine Hydrochloride
Drug: Placebo

First Posted Date: 2009-09-03

Last Posted Date: 2012-09-24

Lead Sponsor: JFK Medical Center

Target Recruit Count: 184

Registration Number: NCT00970944

Locations: 🇺🇸
Methodist Rehabilitation Center, Jackson, Mississippi, United States
🇺🇸
Braintree Rehabilitation Hospital, Braintree, Massachusetts, United States
🇺🇸
Columbia University, New York, New York, United States

and more 8 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy